Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment

Atopic dermatitis (AD) is a chronic autoimmune inflammatory skin disorder which causes a significant clinical problem due to its prevalence. The ongoing treatment for AD is aimed at improving the patient's quality of life. Additionally, glucocorticoids or immunosuppressants are being used in sy...

Full description

Saved in:
Bibliographic Details
Main Authors: Núria Garrós (Author), Paola Bustos-Salgados (Author), Òscar Domènech (Author), María José Rodríguez-Lagunas (Author), Negar Beirampour (Author), Roya Mohammadi-Meyabadi (Author), Mireia Mallandrich (Author), Ana C. Calpena (Author), Helena Colom (Author)
Format: Book
Published: MDPI AG, 2023-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_f52ad5d89c9045a4a7eeca86f99d4b1a
042 |a dc 
100 1 0 |a Núria Garrós  |e author 
700 1 0 |a Paola Bustos-Salgados  |e author 
700 1 0 |a Òscar Domènech  |e author 
700 1 0 |a María José Rodríguez-Lagunas  |e author 
700 1 0 |a Negar Beirampour  |e author 
700 1 0 |a Roya Mohammadi-Meyabadi  |e author 
700 1 0 |a Mireia Mallandrich  |e author 
700 1 0 |a Ana C. Calpena  |e author 
700 1 0 |a Helena Colom  |e author 
245 0 0 |a Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment 
260 |b MDPI AG,   |c 2023-06-01T00:00:00Z. 
500 |a 10.3390/ph16060894 
500 |a 1424-8247 
520 |a Atopic dermatitis (AD) is a chronic autoimmune inflammatory skin disorder which causes a significant clinical problem due to its prevalence. The ongoing treatment for AD is aimed at improving the patient's quality of life. Additionally, glucocorticoids or immunosuppressants are being used in systemic therapy. Baricitinib (BNB) is a reversible Janus-associated kinase (JAK)-inhibitor; JAK is an important kinase involved in different immune responses. We aimed at developing and evaluating new topical liposomal formulations loaded with BNB for the treatment of flare ups. Three liposomal formulations were elaborated using POPC (1-palmitoyl-2-oleoyl-glycero-3-phosphocholine), CHOL (Cholesterol) and CER (Ceramide) in different proportions: (i) POPC, (ii) POPC:CHOL (8:2, mol/mol) and (iii) POPC:CHOL:CER (3.6:2.4:4.0 mol/mol/mol). They were physiochemically characterized over time. In addition, an in vitro release study, ex vivo permeation and retention studies in altered human skin (AHS) were also performed. Histological analysis was used to study the tolerance of the formulations on the skin. Lastly, the HET-CAM test was also performed to evaluate the irritancy capacity of the formulations, and the modified Draize test was performed to evaluate the erythema and edema capacity of the formulations on the altered skin. All liposomes showed good physicochemical properties and were stable for at least one month. POPC:CHOL:CER had the highest flux and permeation, and the retention in the skin was equal to that of POPC:CHOL. The formulations exhibited no harmful or irritating effects, and the histological examination revealed no changes in structure. The three liposomes have shown promising results for the aim of the study. 
546 |a EN 
690 |a liposomes 
690 |a baricitinib 
690 |a JAK-inhibitor 
690 |a transepidermal delivery 
690 |a skin permeation 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 16, Iss 6, p 894 (2023) 
787 0 |n https://www.mdpi.com/1424-8247/16/6/894 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/f52ad5d89c9045a4a7eeca86f99d4b1a  |z Connect to this object online.